Clinical trials: Duloxetine
Drug-induced Liver Injury
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Drug re-administration or rechallenge should be avoided after drug-induced liver injury (DILI) to avoid recurrent and fatal injury. Rechallenge outcomes vary considerably by drug and patient subjects.
- Trial name
- NCT01584765
- Testing
- Prescription drugs with known hepatotoxicity
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder (MDD)
Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder
The purpose of this study is using Duloxetine Hydrochloride Enteric Capsules as the positive control, to evaluate the efficacy and safety of Levomilnacipran Hydrochloride Extended-Release Capsules in patients with Major…
- Trial name
- NCT07253207
- Testing
- Levomilnacipran Hydrochloride Extended-Release Capsules, Duloxetine Hydrochloride Enteric Capsules
- Where
- 28 sites in China
- Volunteers
- 392 people
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436149
- Testing
- SPD489 (Lisdexamfetamine dimesylate )
- Where
- 85 sites in United States, Canada and 4 more
- Volunteers
- 1,262 people
- Sponsor
- Shire
Depressive Disorder, Major
Duloxetine in the Treatment of Melancholic Depression
The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose.
- Trial name
- NCT00191685
- Testing
- duloxetine
- Where
- 23 sites in Australia, Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Idiopathic Parkinson Disease
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.
- Trial name
- NCT00437125
- Testing
- Duloxetine hydrochloride
- Where
- 13 sites in Italy
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
A Study of Duloxetine in Elderly Generalized Anxiety Disorder
The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).
- Trial name
- NCT01118780
- Testing
- Duloxetine
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
- Trial name
- NCT00849901
- Testing
- duloxetine, fluoxetine
- Where
- 59 sites in United States, France and 5 more
- Volunteers
- 337 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathic Pain
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
To evaluate the safety and efficacy of ABT-652 compared to Placebo in subjects with diabetic neuropathic pain. People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or…
- Trial name
- NCT01579279
- Testing
- ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg
- Where
- 8 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder
The primary objective of this study was to compare the efficacy of escitalopram with that of duloxetine in outpatients with Major Depressive Disorder (MDD) after 24 weeks of treatment.
- Trial name
- NCT01148472
- Testing
- Escitalopram, Duloxetine
- Volunteers
- 294 people
- Sponsor
- H. Lundbeck A/S
Fibromyalgia
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS). This trial consists of two distinct study periods.
- Trial name
- NCT01237587
- Testing
- Duloxetine
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 184 people
- Sponsor
- Eli Lilly and Company
Depression
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
The primary purpose of this study is to determine if duloxetine plus non-drug intervention is more effective than duloxetine alone in patients with depression.
- Trial name
- NCT00494377
- Testing
- duloxetine
- Where
- Austria
- Volunteers
- 940 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Study of Desvenlafaxine in Treating Major Depressive Disorder.
The primary purpose of this study is to evaluate if the effectiveness of desvenlafaxine succinate sustained-release tablet (50 mg/day) used for 8 weeks is not inferior to duloxetine hydrochloride enteric-coated capsule (60…
- Trial name
- NCT04364997
- Testing
- Duloxetine Hydrochloride Enteric-coated Capsule
- Where
- China
- Volunteers
- 420 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
Depression
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
The purpose of this study is to compare duloxetine with other antidepressants in the treatment of severe depression.
- Trial name
- TRY FIRST (NCT00666757)
- Testing
- duloxetine, fluoxetine, citalopram
- Where
- 61 sites in United States
- Volunteers
- 750 people
- Sponsor
- Eli Lilly and Company
Painful Diabetic Peripheral Neuropathy
Efficacy of Pregabalin and Duloxetine in Patients With PDPN: the Effect of Pain on Cognitive Function, Sleep and Quality of Life
The objective and the purpose of the trial is to: assess the efficacy of Pregabalin Krka and Dulsevia® in patients with PDPN, investigate the effect of Pregabalin Krka and Dulsevia® on pain and on quality of life (QOL)…
- Trial name
- BLOSSOM (NCT04246619)
- Testing
- Pregabalin, Duloxetine
- Where
- 13 sites in Croatia, North Macedonia and 3 more
- Volunteers
- 254 people
- Sponsor
- KRKA
Urinary Incontinence, Stress
Efficacy and Safety Stress Urinary Incontinence Study
Study F1J-MC-SBBT will examine the effect of duloxetine treatment in women with SUI. The inclusion and exclusion criteria of this Phase 3 study will ensure that all subjects have a clinical diagnosis of SUI.
- Trial name
- NCT00475358
- Testing
- Duloxetine
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Painful Diabetic Peripheral Neuropathy (PDPN)
Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral Neuropathy
A phase 3, prospective, adaptive, randomized, multicenter, double-blind, triple-masked, parallel clinical trial to evaluate the efficacy and safety of N0750 in relieving pain associated with painful diabetic peripheral neuropathy…
- Trial name
- ENFORCE (NCT06715462)
- Testing
- N0750, Cymbalta®, Lyrica®
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Depression
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of the study is to evaluate the efficacy of study drug (BMS-820836) as compared with continued duloxetine in the treatment of patients with treatment resistant depression (TRD).
- Trial name
- NCT01309945
- Testing
- Duloxetine, BMS-820836
- Where
- 84 sites in United States, Canada and 4 more
- Volunteers
- 889 people
- Sponsor
- Bristol-Myers Squibb
Osteoarthritis of the Knee
An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)
The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year.
- Trial name
- NCT02335346
- Testing
- Duloxetine
- Where
- Japan
- Volunteers
- 93 people
- Sponsor
- Eli Lilly and Company